Stockscreener 앱 받기
0.1927
43.32%
-0.1473
시간 외 거래:
.22
0.0273
+14.17%
전일 마감가:
$0.34
열려 있는:
$0.3
하루 거래량:
56.89M
Relative Volume:
3.58
시가총액:
$45.23M
수익:
$48.47M
순이익/손실:
$-170.37M
주가수익비율:
-0.257
EPS:
-0.7499
순현금흐름:
$-171.35M
1주 성능:
-43.11%
1개월 성능:
-56.79%
6개월 성능:
-93.68%
1년 성능:
-81.47%
1일 변동 폭
$0.1626
$0.30
1주일 범위
$0.1626
$0.3551
52주 변동 폭
$0.1626
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.1927 | 79.80M | 48.47M | -170.37M | -171.35M | -0.7499 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-02-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, Inc. Investors to Secure Counsel ... - Caledonian Record
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Gossamer Bio, - GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regencell Bioscience Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGC - GlobeNewswire Inc.
Gossamer Bio (GOSS) Reports Mixed Results for PROSERA in Q1 2026 Earnings Call - GuruFocus
Gossamer targets September 2026 seralutinib NDA filing with potential Q3 2027 approval - MSN
GOSS Reports $99.2 Million in Cash Reserves for Future Operations - GuruFocus
Gossamer Bio (GOSS) Launches Exchange Offer for Convertible Notes - GuruFocus
Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire
Gossamer Bio Q1 2026 Deep Dive: EPS Misses by 17.6%, Revenue Up 72% - AlphaStreet
GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - GlobeNewswire
GOSS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026 - Bluefield Daily Telegraph
GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. - GlobeNewswire
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Gossamer Bio Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Gossamer Bio Shares Decline After Wider-Than-Expected Q1 Loss Despite Revenue Beat (GOSS) - Yahoo Finance
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 - PharmiWeb.com
Gossamer Bio earnings missed by $0.03, revenue topped estimates - Investing.com Canada
Earnings call transcript: Gossamer Bio Q1 2026 shows revenue beat, EPS miss - Investing.com Canada
Gossamer Bio Releases Q1 2026 Financial Results - AlphaStreet
Gossamer Bio Q1 Earnings Call Highlights - MarketBeat
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Gossamer Bio Q1 2026 Earnings Call Transcript - MarketBeat
Gossamer Bio stock falls 5% on earnings miss despite revenue beat By Investing.com - Investing.com South Africa
Gossamer Bio stock falls 5% on earnings miss despite revenue beat - Investing.com India
Q1 2026 Gossamer Bio Inc Earnings Call Transcript - GuruFocus
GOSS: Seralutinib showed significant vascular benefits in PAH, with a major debt reduction plan underway - TradingView
GOSS Reports Strong Q1 Revenue and Advances Regulatory Efforts - GuruFocus
Gossamer Bio Restructures Debt and Advances Seralutinib Program - TipRanks
Gossamer Bio launches exchange offer for convertible notes - Investing.com
Gossamer Bio Enters Noteholder Support Pact to Advance Convertible Notes Exchange - TradingView
Gossamer Bio Q1 net loss widens on higher R&D expenses - TradingView
Gossamer Bio (GOSS) proposes $72M secured notes, 317.6M shares and 150M warrants in debt swap - Stock Titan
Gossamer Bio launches exchange offer and consent solicitation intended to eliminate over $120 million of debt with existing noteholder support - marketscreener.com
Debt exchange and FDA path shape Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support - Yahoo Finance
BRIEF-Gossamer Bio Q1 EPS USD -0.2 - TradingView
GOSS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Gossamer Bio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Gossamer Bio Inc stock (US38198T1034): Q1 2026 earnings in focus after steep share price slide - AD HOC NEWS
Gossamer Bio, Inc.Common Stock (NQ: GOSS - FinancialContent
Gossamer Bio stock (US38198T1034): FDA decision and restructuring put focus on future pipeline - AD HOC NEWS
GOSS SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Gossamer - The National Law Review
GOSS Should I Buy - Intellectia AI
Gossamer Bio to Announce First Quarter 2026 Financial Results and - The National Law Review
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Gossamer Bio: Q1 Earnings Snapshot - Barchart.com
Earnings Preview: Gossamer Bio to Report Financial Results Post-market on May 18 - Moomoo
Gossamer Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gossamer Bio, Inc. 1Q 2026: Revenue $16.96M, EPS ($0.2) — 10-Q Summary - TradingView
Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Gossamer Bio (NASDAQ: GOSS) warns on going concern as Q1 loss widens - Stock Titan
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.53%
자본화:
|
볼륨(24시간):